The most critical component of a brain implant is not the electrode array or the wireless antenna. It is the tiny, custom-built integrated circuit that powers it, reads neural signals, and delivers stimulation, all while sipping power to avoid cooking brain tissue. MintNeuro, a spinout from Imperial College London, is betting that the next generation of neural devices will be built on its purpose-built silicon, not on general-purpose electronics.
Founded in 2023, the company has quietly secured over $20 million in combined venture funding and major research grants to develop its modular semiconductor platform. Its target customer is not the patient, but the medical device company or system integrator looking to build a smaller, more capable, and more energy-efficient implant. In a field dominated by full-stack pioneers like Neuralink, MintNeuro is carving out a role as the essential chip supplier [Imperial College London, Nov 2023].
The Foundry for Neural Silicon
MintNeuro’s commercial proposition is a classic hardware wedge: sell the enabling technology, not the end product. The company designs and supplies ultra-low-power application-specific integrated circuits (ASICs) for sensing and stimulation. These chips are the core of any active implantable medical device, whether for treating epilepsy, Parkinson’s disease, or depression through brain-computer interfaces (BCIs).
The technical argument is straightforward. Building a neural implant from off-the-shelf microcontrollers and radio chips creates a system that is larger, less efficient, and harder to miniaturize. A purpose-built ASIC can integrate the analog front-end for reading microvolt neural signals, the digital processing to interpret them, and the precise current sources for stimulation into a single, power-optimized package. This is the kind of deep, patient engineering that defines a hardware moat; it is not something a software-focused BCI team can easily replicate in-house [Neurofounders, May 2026].
Capitalizing Academic Roots
The company’s foundation is deeply academic, emerging from a decade of neural interface research at Imperial College London. The founding team reflects this pedigree, combining technical, clinical, and commercial expertise.
| Role | Name | Background |
|---|---|---|
| CEO | Dorian Haci | PhD, led the Imperial spin-out process. |
| CTO | Timothy G. Constandinou | Professor of neural interface electronics at Imperial. |
| CSO | Professor Andrew Jackson | Professor of neural interfaces at Newcastle University. |
| Co-founder | Professor Tim Denison | Expert in bioelectronic medicine. |
This team has leveraged its institutional connections to secure non-dilutive funding that de-risks the long hardware development cycle. In 2023, MintNeuro, Imperial, and King’s College London secured a £1.4 million grant from the UK’s National Institute for Health and Care Research (NIHR) to develop a wireless intracranial monitoring device for epilepsy [Imperial College London, Nov 2023]. More significantly, the team is involved in projects that have won a collective £17 million from the UK’s Advanced Research and Invention Agency (ARIA) to advance clinical adoption of chip-scale neurotechnologies [Imperial College London, Nov 2023].
Traction Through Partnerships
For a hardware component company, the clearest signal of traction is a design-win with a systems builder. MintNeuro announced its first major partnership in May 2026 with Motif Neurotech, a company developing an implantable platform for mental health treatment. The deal will see MintNeuro’s chips integrated into Motif’s therapeutic BCI system, a concrete validation of its technology and business model [Medical Device Network, May 2026].
The company is also actively scaling its engineering capability. Job postings for senior mixed-signal IC design and ASIC validation roles point to an ongoing push to bring its chip designs to tape-out and production [MintNeuro, retrieved 2024]. This build-out is supported by venture capital, including a $5 million seed round closed in 2026 [PR Newswire, Aug 2026].
The Scale and Integration Challenge
The path for a component supplier in medical devices is notoriously long and fraught with integration risk. MintNeuro’s success hinges on convincing device makers to bet their multi-year, nine-figure regulatory pathways on an external silicon partner. The technical breakdown of this challenge reveals a few critical pressure points.
First is system-level validation. A neural implant chip does not operate in a vacuum. Its performance is dictated by the electrode interface, the firmware, the wireless link, and the body’s environment. MintNeuro must provide not just a chip, but a complete reference design and support to ensure its silicon works flawlessly within a customer’s unique system architecture.
Second is regulatory co-ownership. Any change to a core component like the ASIC can trigger a substantial re-submission to bodies like the FDA or EMA. MintNeuro’s designs will need to be frozen and manufactured in a certified supply chain long before a partner’s device sees a patient, locking in both technical and commercial relationships.
Finally, there is the economic model. The total addressable market for implantable neural devices, while growing, is still measured in thousands to tens of thousands of units annually, not millions. A chipmaker must command a significant price per unit to build a venture-scale business on that volume, which requires demonstrating unequivocal value in reducing device size, extending battery life, or improving therapeutic efficacy.
The Next Twelve Months
The coming year will be decisive for MintNeuro’s transition from research project to commercial supplier. Key milestones will be less about publicity and more about quiet, technical execution.
- First silicon. Delivering functional, tested chips from its initial tape-out to partners like Motif Neurotech is the paramount objective.
- Additional design wins. Securing a partnership with a developer in a different therapeutic area, such as movement disorders, would prove the platform’s versatility.
- Supply chain lock-in. Establishing relationships with a certified semiconductor foundry for volume production is a necessary, unglamorous step.
The company’s substantial grant funding provides a long runway to navigate these steps without the immediate revenue pressure that sinks many deep-tech startups. If MintNeuro can successfully ship its silicon and embed it within even a handful of next-generation clinical devices, it will have secured a foundational role in the building of the brain-computer interface itself.
Sources
- [Imperial College London, Nov 2023] Inspiration turns into application: Imperial’s neural interface research leads to new spinout MintNeuro | https://www.imperial.ac.uk/news/260636/inspiration-turns-into-application-imperials-neural/
- [Neurofounders, May 2026] MintNeuro and Motif Neurotech Partner to Advance Miniature Brain-Computer Interface Therapy for Mental Health | https://www.neurofounders.co/press-releases/mintneuro-and-motif-neurotech-partner-to-advance-miniature-brain-computer-interface-therapy-for-mental-health
- [Medical Device Network, May 2026] MintNeuro and Motif Neurotech partner on brain-computer interface therapy | https://www.medicaldevice-network.com/news/mintneuro-motif-neurotech-brain-computer-interface-therapy/
- [PR Newswire, Aug 2026] MintNeuro raises $5 million to scale purpose-built chip platform for neural devices and brain-computer interfaces | https://www.prnewswire.com/news-releases/mintneuro-raises-5-million-to-scale-purpose-built-chip-platform-for-neural-devices-and-brain-computer-interfaces-302900235.html
- [MintNeuro, retrieved 2024] MintNeuro Careers Page | https://mintneuro.com/careers-senior-mixed-signal-ic-design-engineer